Description
An inhibitor of NAD-dependent deacetylase activity of human SIRT1 (IC₅₀ = 56 µM) and SIRT2(IC₅₀ = 59 µM). Acts as an antitumor agent. Treatment of BCL6-expressing Burkitt lymphoma cells with Cambinol induces apoptosis accompanied by hyperacetylation of BCL6 and p53.
Cambinol is an inhibitor of NAD-dependent deacetylase activity of human SIRT1 (IC₅₀ = 56 µM) and SIRT2(IC₅₀ = 59 µM). Acts as an antitumor agent.
Alternate Name/Synonyms: 5-[(2-hydroxy-5,8-dihydronaphthalen-1-yl)methyl]-6-phenyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; NSC-112546
Appearance: White solid
Formulation: N/A
CAS Number: 14513-15-6
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₁H₁₆N₂O₂S
Molecular Weight: 360.43
Cell-Permeable?: Yes
Purity: ≥95% by HPLC
Solubilities: DMSO (10 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A SIRT1 inhibitor
MDL Number: MFCD09057543
PubChem CID: 3246390
SMILES: C1=CC=C(C=C1)C2=C(C(=O)NC(=S)N2)CC3=C(C=CC4=CC=CC=C43)O
InChi: InChI=1S/C21H16N2O2S/c24-18-11-10-13-6-4-5-9-15(13)16(18)12-17-19(14-7- 2-1-3-8-14)22-21(26)23-20(17)25/h1-11,24H,12H2,(H2,22,23,25,26)
InChi Key: RVNSQVIUFZVNAU-UHFFFAOYSA-N
Additional Information
Storage Condition: |
+4°C |
Shipping Condition: |
RT |
Shelf Life: |
24 months |